CVB homepage

pharmaceutical drug approval process

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.

Medtronic has received U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI was designed to provide real-time insights for users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app and Medtronic’s disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval back in August.

Medtronic designed its new Smart MDI system to provide real-time insights to users on multiple daily injection therapy.

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."